Pureos Bioventures

Exciting update from our portfolio company Ariceum Therapeutics! Congratulations for starting the Phase 1 first-in-human clinical trial (CITADEL-123) of its targeted radiotherapy candidate ATT001 - an Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma! https://lnkd.in/d65A_My6

Reflecting on a great Festival of Biologics 2024 in Basel! It was a fantastic event filled with thought-provoking panels, dynamic discussions, and the perfect opportunity to reconnect with familiar faces and to build new relationships.   It was a pleasure to join the panel discussion in finance & investment for Start-ups with Dominik Escher, Managing Partner representing Pureos Bioventures and the very insightful keynote panel discussion “Accelerating ADC and Bioconjugate Development" with Dragan Grabulovski (Araris Biotech AG) and Jack Elands (Adcytherix) representing two Pureos Portfolio companies. Looking forward to the Festival of Biologics 2025!

Exciting news from our portfolio company PulseSight Therapeutics! We're thrilled to announce that their team will present groundbreaking data on PST-611 at the 2024 EVER Congress in Valencia, Spain.   PST-611 is a new possible treatment against geographic atrophy (GA) secondary to dry AMD by restoring iron homeostasis to protect retinal cells. The company is about to submit a clinical trial authorization (CTA) by end October to start clinical development of this exciting new mode of action in GA.   Join PulseSight for: Oral Presentation by Dr. Thierry Bordet (CSO) on November 5th, 2024; 09:20-10:35 CET Poster Presentation by Dr. Karine BIGOT on November 5th, 2024; 11:05-12:05 CET  

We are thrilled to announce that our portfolio company Alentis Therapeutics has received FDA IND clearance for ALE.P02, a first-in-class Claudin-1 antibody-drug conjugate (ADC) designed to target squamous cancers. This marks a significant milestone as ALE.P02 becomes the first anti-Claudin-1 ADC to enter the clinic. Alentis' innovative approach has the potential to address critical unmet needs in cancer treatment, and the company will start the Phase 1 clinical trial in patients in Q1 2025. Congrats to the Alentis team! https://lnkd.in/eQU3Hd5y

Exciting update from our portfolio company Acrivon Therapeutics, Inc. Therapeutics at ESMO - European Society for Medical Oncology! Acrivon announces positive endometrial cancer data from ongoing ACR-368 Phase 2 registrational study - showing a confirmed ORR of 62.5% in endometrial cancer patients and encouraging safety profile. Additionally, advancement of ACR-2316 into clinical trials ahead of timelines, and progress on AP3 Interactome for proprietary data analysis. We are thrilled with the positive updates from Acrivon as they rapidly advance their clinical pipeline, and we eagerly anticipate their continued progress! https://lnkd.in/e4BurzaG

We hosted an inspiring "AI in Biotech" event featuring prominent experts Noëmi Thum, Christof Zogg, Gisbert SCHNEIDER, Sai Reddy, and Lars Nieba. The event focused on the transformative power of artificial intelligence and its profound implications for our lives as well as more specifically in healthcare and life sciences. They shared valuable insights into how AI is revolutionizing the development of new and more effective medicines, and even discussed its potential to predict future pandemics. This event clearly demonstrated transformative power of AI for the biotech sector, enabling a revolution across various fields, and hinting at even more possibilities for the future. We are proud to join this inspiring development with our portfolio companies like Engimmune Therapeutics and look forward to continuing to support this endeavour. A big thank you to all participants!

Exciting update from our portfolio company PulseSight Therapeutics! PulseSight strengthens its leadership in ophthalmology by establishing an Scientific and Clinical Advisory Board (SAB). The SAB members from Europe, the USA, and Australia bring decades of expertise in clinical practice and scientific research, spanning both fundamental and clinical studies of retinal and macular diseases. We warmly welcome on board Frank G. Holz, Francine Behar-Cohen, Dr. Joshua Dunaief, Robyn Guymer AM and Eleonora (Nora) Lad! https://lnkd.in/dXx6qE6k

Exciting update from our portfolio company ImCheck Therapeutics! ImCheck proudly announced today that it has received EUR 20 million in non-dilutive funding as part of the “i-Démo” call for projects in support of France's 2030 ambitious vision to deliver 20 innovative biomedicines by the end of the decade. Looking forward to help bringing new medicines to patients! https://lnkd.in/eNAQB5bi

Congratulations to our portfolio company Mediar Therapeutics for starting their second clinical program, a Phase 1 trial evaluating safety and tolerability of MTX-474, a human IgG1 antibody designed to neutralize EphrinB2 signaling. We are excited about this important milestone and look forward to bringing new treatments to patients with fibrotic diseases. https://lnkd.in/gM2pqQEy

Looking back at a fantastic Asia Summit on Global Health 2024 with insightful panels and discussions and great opportunities to catch up with old friends and make new connections. Great to join the panel about fostering collaboration for next-gen healthcare business with Martin Münchbach representing Pureos Bioventures, with Christopher Chao from The Hong Kong Polytechnic University, with @Hu Huidong from Genertec Meheco, with Dimitry Tran from Harrison.ai as well as Anita Ou from HSBC and supporting the ever growing and inspiring HongKong Biotech Scene. Thank you to Weng-Li Yoon from HKSTP - Hong Kong Science and Technology Parks Corporation, Emily C. and Dr. Maggie Lo (Palmer)盧靜敏 from Office for Attracting Strategic Enterprises, Andy Wong from Invest Hong Kong, Patrick Lau 刘会平 from Hong Kong Trade Development Council, and Simon Law and Ir. Andrew Young of the Sino Group for the excellent discussions at ASGH 2024! Looking forward to seeing you next year!